CMS finalizes policies to enhance consumer protections, promote competition, and expand access to care for Medicare Advantage (MA) and Medicare Part D; digital therapeutic Rejoyn receives FDA clearance for adults with major depressive disorder (MDD); study reveals minimal symptom reduction from nirmatrelvir–ritonavir (Paxlovid) in high-risk, fully vaccinated patients.
Washington, Apr 4 (Prensa Latina) Rejoyn, the first digital prescription treatment against major depressive disorder, received the green light from the United States Food and Drug Administration; however, some experts remain skeptical about this initiative.